Page last updated: 2024-12-05

butaperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Butaperazine is a phenothiazine derivative that acts as an antipsychotic. It is structurally related to other phenothiazines such as chlorpromazine. Its mechanism of action is thought to involve antagonism of dopamine receptors in the brain. Butaperazine is used to treat schizophrenia and other psychotic disorders. However, its use has been limited due to potential side effects including extrapyramidal symptoms (EPS) such as tremors and muscle rigidity. Research into butaperazine has focused on understanding its pharmacological properties, its therapeutic efficacy, and its potential for the treatment of other neurological disorders. Studies have investigated its effects on anxiety, depression, and Parkinson's disease. The synthesis of butaperazine involves several steps starting with the reaction of a substituted aniline with a substituted diphenylmethane compound. Butaperazine has been studied in preclinical models of various diseases, including schizophrenia, Parkinson's disease, and Alzheimer's disease. Despite its potential therapeutic value, butaperazine has not been widely used in clinical practice. Further research is needed to evaluate its safety and efficacy in different patient populations.'

butaperazine: was heading 1964-94 (Prov 1964-73); use PHENOTHIAZINES to search BUTAPERAZINE 1966-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12598
CHEMBL ID1697826
CHEBI ID135663
SCHEMBL ID119995
MeSH IDM0224697

Synonyms (61)

Synonym
butaperazina
butaperazinum
unii-txp4t9106s
txp4t9106s ,
1-butanone, 1-[10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazin-2-yl]-
butaperazine
1-{10-[3-(4-methylpiperazin-1-yl)propyl]-10h-phenothiazin-2-yl}butan-1-one
perazine, (1-oxobutyl)-
emerex
randolectil
1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-
butyrylyperazine
megalectil
butyrylperazine
butaperazina [inn-spanish]
einecs 211-493-9
hsdb 3297
3-n-butyryl-10-(3'-n-methyl-piperazino-n'-propyl)phenothiazin
butaperazinum [inn-latin]
butaperazine [usan:inn]
bayer 1362
ahr 712
1-{10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl}-1-butanone
repoise
n-(gamma-(4'-methyl-1'-piperazinyl)propyl)-3-butyrylphenothiazine
2-butyryl-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
ahr-712
perazine, butyryl-
riker 595
D02642
butaperazine (usan)
653-03-2
1- 10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl -1-butanone
1-(10-(3-(4-methyl-1-piperazinyl)-propyl)-10h-phenothiazin-2-yl)-1-butanone
1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)-10h-phenothiazin-2-yl)-
1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-1-butanone
CHEBI:135663
1-[10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazin-2-yl]butan-1-one
bayer-1362
CHEMBL1697826
riker-595
ahr-3000
SCHEMBL119995
butaperazine [who-dd]
butaperazine [mi]
butaperazine [inn]
butaperazine [hsdb]
butaperazine [usan]
1-{10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazin-2-yl}-1-butanone
1-(10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazin-2-yl)-1-butanone
2-butyryl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine
DVLBYTMYSMAKHP-UHFFFAOYSA-N
3-n-butyryl-10-(3'-n-methyl-piperazino-n'-propyl)phenothiazine
1-(10-[3-(4-methyl-1-piperazinyl)propyl]-10h-phenothiazin-2-yl)-1-butanone #
DTXSID1022712
Q5002359
DB13213
bdbm50497150
butyrylperazine; emerex; megalectil
EN300-19748930
AKOS040745640
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1148006Binding affinity to bovine serum albumin by circular dichroic probe technique1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1148003Dissociation constant, pKa of the compound by UV-visible spectrophotometer analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1148004Oleyl alcohol-water partition coefficient, Rm of the compound measured at 0% methanol by reverse-phase thin layer chromatography1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (92.59)18.7374
1990's0 (0.00)18.2507
2000's2 (7.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.31 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]